(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the Congressional Budget Office’s (CBO) $43 billion score of point-of-sale rebates in Medicare Part D. CBO’s score is the latest in a series of official estimates
A new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the point-of-sale in Medicare Part D, total beneficiary premiums could increase by an estimated $28.7 billion (16%) and total Federal government
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the Medicare Part D final rule released yesterday by the Department of Health and Human Services: “Two years ago drugmakers launched a
“This extra year will help to reduce disruptions to Medicare beneficiaries by allowing Part D plans time to adjust their pay-for-performance pharmacy contracting,” PCMA said. “In addition, the delay appropriately prevents premiums from increasing in 2023 on top of rising inflation.”
“We are currently reviewing the proposed rule. However, previous point-of-sale proposals in Medicare have not advanced because they would significantly increase Medicare spending,” said JC Scott, president and CEO of the PBM advocacy group Pharmacy Care Management Association in a statement.
“This score strikes the third blow to the drug makers’ long-running, multi-million dollar campaign to shift blame for their own prices onto the health plans and…PBMs that negotiate discounts and rebates to reduce costs. For policymakers, this should be a ‘three strikes and
“I think what happened is they looked at this policy very, very closely and found out it was a loser,” PCMA President Mark Merritt said.
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. RX DRUG AFFORDABILITY BOARDS: NO PRICE SETTING & COME ONE, COME
New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for Majority of Beneficiaries (Washington, D.C.) — A new report, “Medicare Part D Pharmacy Price Concessions at the Point of Sale, Potential Impacts
(Washington, D.C.) — As the independent drugstore lobby descends on Capitol Hill this week to push for costly new government health mandates, the Pharmaceutical Care Management Association (PCMA) continues to highlight how pharmacy benefit managers (PBMs) reduce prescription drug costs and improve
©2024 PCMA. All Rights Reserved.
